Main > ONCOLOGY (**) > Perivascular Epithelioid Cell Tumor > TREAT.: > USA. A. mTOR Inhibitor NAB IV Inj.
USA. A. mTOR Inhibitor NAB IV Inj.'s subsections
(*) USA Approval Date: 2021. 11.23
(*) USA Launch Date: 2022. 02.23.
(PEComa)
Company
Generic Name: Sirolimus
Locally Advanced Unresectable or>
mTOR: mechanistic Target Of Rapamyc
NAB: Nanoparticle Albumin Bound
Patent.Total USA No.: 4
Patent>Assignee; Claims; No.; Etc.
Patent>UpDate: 2022. 02.22
Product Web-Site
USA. A. mTOR Inhibitor NAB IV Inj.'s products
This section has no products